Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data

•HCC is a poorly treated cancer and its incidence is increasing rapidly worldwide.•The combination of checkpoint inhibitors and anti-angiogenic therapy has improved survival in patients with unresectable HCC.•Some patients respond well to checkpoint inhibitors, but many attain no benefit or in some...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Seminars in cancer biology 2022-11, Vol.86 (Pt 3), p.799-815
Hauptverfasser:	Harkus, Uasim, Wankell, Miriam, Palamuthusingam, Pranavan, McFarlane, Craig, Hebbard, Lionel
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Immunological - therapeutic use Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Hepatocellular carcinoma Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immune checkpoints Immunotherapy Immunotherapy - methods Liver Neoplasms - drug therapy Liver Neoplasms - genetics Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!